ME02694B - Bezvodni kristalni oblik dimetoksi docetaksela i postupci za njegovu pripremu - Google Patents

Bezvodni kristalni oblik dimetoksi docetaksela i postupci za njegovu pripremu

Info

Publication number
ME02694B
ME02694B MEP-2016-280A MEP28016A ME02694B ME 02694 B ME02694 B ME 02694B ME P28016 A MEP28016 A ME P28016A ME 02694 B ME02694 B ME 02694B
Authority
ME
Montenegro
Prior art keywords
hydroxy
fact
indicated
methods
mixture
Prior art date
Application number
MEP-2016-280A
Other languages
English (en)
Inventor
Pascal Billot
Marielle Dufraigne
Hagit Elmaleh
Alexandre Guiliani
Fabrice Mangin
Patricia Rortais
Lionel Zaske
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02694(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ME02694B publication Critical patent/ME02694B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (4)

1. Bezvodni oblik D (2R,3S)-3-ter-butoksikarbonilamino-2-hidroksi-3-fenilpropionata 4aacetoksi-2a-benzoiloksi-5P,20-epoksi-l P-hidroksi-7p, 1 op-ctimetoksi-9-okso-taks-11-en-13aila naznacen time sto postoji dijagram DRXP koji prikazuje karakteristike koje se nalaze u 3.9, 7.7, 7.8 , 7.9 , 8.6, 9.7, 10.6, 10.8, 11.1 i 12.3 ± 0.2 stepeni 2-Theta.
2.Postupak za pripremu bezvodnog oblika D prema zahtevu 1 naznacen time sto se izvodi putem kristalizacije na sobnoj temperaturi oblika A acetonskog solvata u ulju posle cega sledi ispiranje heptanom .
3.Postupak za pripremu bezvodnog oblika D prema zahtevu 1 naznacen time sto se izvodi putem kristalizacije u toku 48 sati pri sobnoj temperaturi rastvora (2R,3 S)-3-tertbutoksikarbonilamino- 2-hidroksi-3-fenilpropionata 4a-acetoksi-2a-benzoiloksi-5p,20-epoksil P-hidroksi-7p, 10P-dimetoksi-9-okso-taks-11-en-13a-ila u smesi polisorbata 80 pH 3.5, etanola i vode.
4.Postupak prema zahtevu 3, naznacen time sto sme5a polisorbata 80 pH 3.5, etanola i vode jeste smesa 25/25/50.
MEP-2016-280A 2008-01-17 2009-01-15 Bezvodni kristalni oblik dimetoksi docetaksela i postupci za njegovu pripremu ME02694B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0800243A FR2926551A1 (fr) 2008-01-17 2008-01-17 Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP09722321.8A EP2247582B1 (fr) 2008-01-17 2009-01-15 Forme cristalline anhydre du diméthoxy docétaxel et ses procédés de préparation
PCT/FR2009/000042 WO2009115655A2 (fr) 2008-01-17 2009-01-15 Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation

Publications (1)

Publication Number Publication Date
ME02694B true ME02694B (me) 2017-10-20

Family

ID=39712334

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2010-114A ME01009B (me) 2008-01-17 2009-01-15 Kristalni oblici dimetoksi docetaksela i postupak za njihovo dobijanje
MEP-2016-280A ME02694B (me) 2008-01-17 2009-01-15 Bezvodni kristalni oblik dimetoksi docetaksela i postupci za njegovu pripremu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2010-114A ME01009B (me) 2008-01-17 2009-01-15 Kristalni oblici dimetoksi docetaksela i postupak za njihovo dobijanje

Country Status (42)

Country Link
US (5) US8378128B2 (me)
EP (2) EP2719694A1 (me)
JP (3) JP5932219B2 (me)
KR (3) KR20150042303A (me)
CN (3) CN101918385B (me)
AR (1) AR070175A1 (me)
AU (1) AU2009227081B2 (me)
BR (1) BRPI0906518A2 (me)
CA (1) CA2712373C (me)
CL (1) CL2009000094A1 (me)
CO (1) CO6351784A2 (me)
CR (1) CR11532A (me)
CY (1) CY1119129T1 (me)
DK (1) DK2247582T3 (me)
DO (3) DOP2010000211A (me)
EA (1) EA017670B1 (me)
EC (1) ECSP10010324A (me)
ES (1) ES2606228T3 (me)
FR (1) FR2926551A1 (me)
HN (1) HN2010001435A (me)
HR (1) HRP20161655T1 (me)
HU (1) HUE032150T2 (me)
IL (2) IL207031A (me)
LT (1) LT2247582T (me)
MA (1) MA32086B1 (me)
ME (2) ME01009B (me)
MX (1) MX2010007840A (me)
MY (1) MY159362A (me)
NI (4) NI201001031A (me)
NZ (3) NZ598289A (me)
PH (1) PH12013500102A1 (me)
PL (1) PL2247582T3 (me)
PT (1) PT2247582T (me)
RS (1) RS55519B1 (me)
SG (1) SG179446A1 (me)
SI (1) SI2247582T1 (me)
TN (1) TN2010000284A1 (me)
TW (3) TW201444813A (me)
UA (1) UA105896C2 (me)
UY (1) UY31602A1 (me)
WO (1) WO2009115655A2 (me)
ZA (1) ZA201105206B (me)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779009A1 (en) 2009-10-29 2011-05-05 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
EA023950B1 (ru) * 2011-04-12 2016-07-29 Тева Фармасьютикалз Интернэшнл Гмбх Твердофазные формы кабазитаксела и способы их получения
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
WO2013069027A1 (en) * 2011-09-26 2013-05-16 Fresenius Kabi Oncology Ltd. Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
WO2013065070A1 (en) 2011-11-01 2013-05-10 Fresenius Kabi Encology Ltd. Amorphous form of cabazitaxel and process for its preparation
DE112012004944T5 (de) 2011-11-28 2014-12-11 Fresenius Kabi Oncology Ltd. Kristalline Formen von Cabazitaxel und deren Herstellungsverfahren
JP6025861B2 (ja) * 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
EP2822932A2 (en) 2012-03-08 2015-01-14 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
US9012665B2 (en) 2012-07-31 2015-04-21 Yung Shin Pharm. Ind. Co., Ltd. Amorphous cabazitaxel
WO2014028704A1 (en) 2012-08-15 2014-02-20 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
KR101429543B1 (ko) * 2012-12-13 2014-08-14 주식회사 삼양바이오팜 카바지탁셀의 신규 결정형 및 그 제조방법
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
CN103910697B (zh) * 2012-12-30 2016-08-03 上海医药工业研究院 卡巴他赛乙酸合物及其结晶
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
EP2938605A4 (en) * 2012-12-31 2016-10-26 Shilpa Medicare Ltd METHOD FOR THE PRODUCTION OF AMORPHIC CABAZITAXEL
WO2014115168A2 (en) * 2013-01-23 2014-07-31 Leiutis Pharmaceuticals Private Limited Novel solvate forms of cabazitaxel and process for preparation thereof
WO2014128728A2 (en) * 2013-02-25 2014-08-28 Laurus Labs Private Limited Solid forms of cabazitaxel and processes for preparation thereof
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
CN103450119B (zh) * 2013-09-24 2015-06-17 天津炜捷制药有限公司 一种卡巴他赛晶型w及其制备方法
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
EP2865675A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
CN104945453B (zh) * 2014-03-28 2018-06-26 江苏天士力帝益药业有限公司 吡唑衍生物的多晶型物
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163837C (en) * 1994-12-13 1999-07-20 Robert K. Perrone Crystalline paclitaxel hydrates
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) * 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
CN1596250A (zh) * 2001-11-30 2005-03-16 布里斯托尔-迈尔斯斯奎布公司 紫杉醇溶剂化物
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
BRPI0606132A2 (pt) * 2005-10-12 2009-06-02 Sicor Inc formas cristalinas de docetaxel e processos para seu preparo
TWI394765B (zh) * 2008-12-12 2013-05-01 Ind Tech Res Inst 難燃水性聚胺基甲酸酯分散液
CA2779009A1 (en) 2009-10-29 2011-05-05 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
DE112012004944T5 (de) 2011-11-28 2014-12-11 Fresenius Kabi Oncology Ltd. Kristalline Formen von Cabazitaxel und deren Herstellungsverfahren
JP6025861B2 (ja) 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法

Also Published As

Publication number Publication date
TW201444813A (zh) 2014-12-01
JP2011509980A (ja) 2011-03-31
TW201444814A (zh) 2014-12-01
US8378128B2 (en) 2013-02-19
MY159362A (en) 2016-12-30
AU2009227081A1 (en) 2009-09-24
RS55519B1 (sr) 2017-05-31
HN2010001435A (es) 2014-02-03
EA017670B1 (ru) 2013-02-28
US20110144362A1 (en) 2011-06-16
PH12013500102A1 (en) 2015-09-16
US20190144406A1 (en) 2019-05-16
FR2926551A1 (fr) 2009-07-24
HRP20161655T1 (hr) 2017-01-27
NI201001033A (es) 2011-04-26
HK1150603A1 (en) 2012-01-06
CN101918385B (zh) 2014-07-02
KR20150042302A (ko) 2015-04-20
TWI477492B (zh) 2015-03-21
PL2247582T3 (pl) 2017-04-28
UY31602A1 (es) 2009-08-31
DOP2010000211A (es) 2010-07-31
US20140350272A1 (en) 2014-11-27
WO2009115655A3 (fr) 2010-04-01
NI201001031A (es) 2011-04-26
UA105896C2 (uk) 2014-07-10
CN104130221A (zh) 2014-11-05
JP5932219B2 (ja) 2016-06-08
AR070175A1 (es) 2010-03-17
LT2247582T (lt) 2017-01-25
CO6351784A2 (es) 2011-12-20
HUE032150T2 (en) 2017-08-28
PT2247582T (pt) 2016-11-16
NZ603797A (en) 2013-05-31
ECSP10010324A (es) 2010-08-31
DK2247582T3 (da) 2017-01-02
WO2009115655A2 (fr) 2009-09-24
IL207031A0 (en) 2010-12-30
IL207031A (en) 2017-11-30
DOP2013000212A (es) 2014-01-31
JP2014074054A (ja) 2014-04-24
NI201000103A (es) 2011-04-26
MX2010007840A (es) 2010-08-04
NZ598289A (en) 2013-06-28
ME01009B (me) 2012-10-20
SI2247582T1 (sl) 2017-03-31
IL229239A0 (en) 2013-12-31
ES2606228T3 (es) 2017-03-23
EP2247582A2 (fr) 2010-11-10
CA2712373C (fr) 2016-06-14
DOP2013000016A (es) 2013-06-15
KR20150042303A (ko) 2015-04-20
ZA201105206B (en) 2013-05-29
TW200944510A (en) 2009-11-01
US20130178639A1 (en) 2013-07-11
EP2719694A1 (fr) 2014-04-16
SG179446A1 (en) 2012-04-27
CA2712373A1 (fr) 2009-09-24
EA201070856A1 (ru) 2011-02-28
CY1119129T1 (el) 2018-02-14
AU2009227081B2 (en) 2013-11-14
BRPI0906518A2 (pt) 2015-07-14
TN2010000284A1 (fr) 2011-11-11
MA32086B1 (fr) 2011-02-01
KR20100103614A (ko) 2010-09-27
CL2009000094A1 (es) 2010-02-12
JP2015163626A (ja) 2015-09-10
CN104130220A (zh) 2014-11-05
CN101918385A (zh) 2010-12-15
CR11532A (es) 2010-11-22
NZ586829A (en) 2012-05-25
US8846959B2 (en) 2014-09-30
NI201001032A (es) 2011-04-26
US10160739B2 (en) 2018-12-25
US20180002302A1 (en) 2018-01-04
EP2247582B1 (fr) 2016-09-07

Similar Documents

Publication Publication Date Title
ME02694B (me) Bezvodni kristalni oblik dimetoksi docetaksela i postupci za njegovu pripremu
EA200900793A1 (ru) Способ получения эзетимиба и его производных
ECSP18063798A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
MX2023004157A (es) Composiciones de oligosacaridos para el uso como alimento para animales y sus metodos para producirlas.
RU2016129184A (ru) Жидкая композиция для электронных сигарет
EP4566677A3 (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
BRPI0923702B8 (pt) Composições inseticidas estáveis compreendendo spinosin e uma mistura esteroisomérica de sulfoxaflor, e seu método de produção
EA201290074A1 (ru) Способы кристаллизации ривароксабана
HN2011001810A (es) Sintesis de espirikpiridinas radiomarcadas con 18f a partir de precursores de tosilato y composiciones farmaceuticas estables de estas.
ECSP13012575A (es) Monohidrato de derivados de aza-adamantano
EA201790384A1 (ru) Полиморфы селинексора
EA201171216A1 (ru) Фенилацетат l-орнитина и способы его получения
MA33063B1 (fr) Complexe d'hydrohalogenure d'agomelatine et procede de preparation de celui-ci
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
MX360062B (es) Metodos de elaboracion de fenilacetato de l-ornitina.
BR112014012892A8 (pt) compostos de reversão anticoagulante e composição farmacêutica compreendendo os referidos compostos
EA201071120A1 (ru) Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
MX376564B (es) Proceso para la preparación de la forma 1 del propionato de fluticasona.
AR076709A1 (es) Piperidinas sustituidas como antagonistas de par-1 y un procedimiento para su preparacion
EA200901616A1 (ru) Пищевые композиции
RU2011143166A (ru) Новые кристаллические формы адефовира дипивоксила и способы его получения
GEP20186827B (en) Process for synthesis of ulipristal acetate and its 4'-acetyl analogue
EA200971019A1 (ru) Способы получения (r)-2-метилпирролидина и (s)-2-метилпирролидина и их солей винной кислоты